{"id":"NCT02339246","sponsor":"Veloxis Pharmaceuticals","briefTitle":"Pharmacokinetic Comparison Of All FK-506 Formulations","officialTitle":"A Steady-state Pharmacokinetic Comparison Of All FK-506 Formulations","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2015-01-15","resultsPosted":"2016-01-18","lastUpdate":"2016-01-18"},"enrollment":32,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"BASIC_SCIENCE"},"conditions":["Renal Failure"],"interventions":[{"type":"DRUG","name":"Prograf vs Envarsus XR vs Astagraf XL","otherNames":["Tacrolimus"]},{"type":"DRUG","name":"Prograf vs Astagraf XL vs Envarsus XR","otherNames":["Tacrolimus"]}],"arms":[{"label":"Prograf vs Envarsus XR vs Astagraf XL","type":"ACTIVE_COMPARATOR"},{"label":"Prograf vs Astagraf XL vs Envarsus XR","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to compare the pharmacokinetic parameters of three different formulations of tacrolimus.\n\nEligible patients will be treated with all three formulations in a pre-defined sequence.","primaryOutcome":{"measure":"Evaluation of T(Max) for Envarsus XR, Astagraf XL and Prograf.","timeFrame":"8 days","effectByArm":[{"arm":"Envarsus XR","deltaMin":5.91,"sd":null},{"arm":"Astagraf XL","deltaMin":1.93,"sd":null},{"arm":"Prograf","deltaMin":1.48,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["29462506","27340950"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":["Diarrhea","Oedema peripheral","Headache","Vomiting","Fatigue"]}}